Trial Profile
A Feasibility Study to Evaluate Lisdexamfetamine Dimesylate (Vyvanse) in Adults With Bulimia Nervosa
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Bulimia nervosa
- Focus Therapeutic Use
- 25 Nov 2020 Status changed from recruiting to discontinued.
- 10 Jun 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 10 Jun 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.